Heart Failure, Chronic Kidney Disease
Conditions
Interventions
Patients who meet the eligibility criteria will be randomised to one of the following treatment group, stratified according to T2DM (yes/no) and eGFR (>=20 to =30 to =45 mL/min/1.73 m2):
- AZD9977 A +
Sponsors
Hibi Kazushige
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Documented diagnosis of stable symptomatic HF (New York Heart Association class II-III) at screening, and a medical history of typical symptoms and signs of HF in those who are currently receiving loop diuretic treatment - Left ventricular ejection fraction 30 mg/g (3 mg/mmol) or more and <3000 mg/g (300 mg/mmol) - Serum/plasma K+ level 3.5 or more and <5.0 mmol/L within 10 days prior to randomization - Serum/ plasma Na+ level within normal reference values within 7 days prior to randomization - Systolic blood pressure should be at protocol defined range at randomization (Visit 3), with no change to antihypertensive treatments in previous 3 weeks - Body mass index less than 40 kg/m^2 - Male or female of non-childbearing potential - All participants must follow protocol defined contraceptives procedures
Exclusion criteria
Exclusion criteria: - Primary glomerulopathy, vasculitic renal disease, prior dialysis or unstable rapidly progressing renal disease, autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis or anti-neutrophil cytoplasm antibody -associated vasculitis - Participants with currently decompensated HF requiring hospitalization for optimization of HF treatment and are not on stable HF therapy at the time of enrollment - HF due to cardiomyopathies - High output HF (e.g., due to hyperthyroidism or Paget's disease) - HF due to pericardial disease, congenital heart disease or clinically significant uncorrected primary cardiac valvular disease or planned cardiac valve repair/replacement - Participants with uncontrolled diabetes mellitus (Glycated hemoglobin >10%) - Participants with Type 1 diabetes mellitus - Intermittent or persistent 2nd or 3rd degree atrioventricular block, sinus node dysfunction with clinically significant bradycardia or sinus pauses, not treated with a pacemaker - History of any life-threatening cardiac dysrhythmia or uncontrolled ventricular rate in participants with atrial fibrillation or atrial flutter - Acute coronary syndrome and/or elective/non-elective percutaneous cardiac interventions (within 3 months) prior to randomisation or is planned to undergo any of these procedures during the study - Any major cardiovascular (eg, open chest, coronary artery bypass grafting or valvular repair/replacement) or major non-cardiovascular surgery within 3 months prior to randomisation (Visit 3) or is planned to undergo any cardiovascular surgery during the study - Heart transplantation or left ventricular assist device at any time or if these are planned - Kidney or any organ transplantation or if these are planned - Medical conditions associated with development of hyperkalaemia (Addison's disease ) - History or ongoing allergy/hypersensitivity, to sodium-glucose co-transporter-2 inhibitor (SGLT2i e.g., dapagliflozin, empagliflozin) - Stroke, transient ischemic attack, carotid surgery, or carotid angioplasty within previous 3 months prior to randomisation - Hepatic disease, including hepatitis and/or hepatic impairment (Child-Pugh class A-C), and aspartate aminotransferase or alanine transaminase or total bilirubin should be in protocol defined range at time of screening and/ or within 7 days prior to randomization - Participants with newly detected pathological laboratory values or an ongoing disease condition - If the participants clinical signs and symptoms consistent with COVID-19, and has been previously hospitalized with COVID-19 infection and did not fully recover their previous health status - Previous randomization in the present study - Prior medical treatment with an mineralocorticoid receptor antagonist where the medication was taken within 90 days prior to screening - Current or prior treatment within 6 months prior to screening with cytotoxic therapy, immunosuppressive therapy, or other immunotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent change from baseline in UACR at 12 weeks [ Time Frame: Baseline (Day 1) until Week 12 (Day 85) ] Evaluating the effect of AZD9977 in combination with dapagliflozin compared with dapagliflozin alone on UACR. | — |
Countries
Belgium, Bulgaria, Canada, Czech Republic, Denmark, Germany, Hungary, India, Italy, Japan, Lithuania, Poland, Russia, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, Turkey, Ukraine, United States
Contacts
Public ContactKazushige Hibi
Astrazeneka K.K
Outcome results
None listed